Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inmed Pharmaceuticals Inc
(NQ:
INM
)
0.4200
-0.0112 (-2.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inmed Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market
March 03, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
March 02, 2022
Via
CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market
March 02, 2022
Via
Investor Brand Network
InMed’s (NASDAQ: INM) Evolution to Commercial Sales Featured in Research Report
February 17, 2022
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report
February 16, 2022
Via
Investor Brand Network
Exposures
Product Safety
InMed (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
February 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Supply Chain
Exposures
Intellectual Property
Supply Chain
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT
February 16, 2022
LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and...
From
Edison Investment Research Limited
Via
AccessWire
Exposures
Product Safety
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report
February 15, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Supply Chain
Exposures
Intellectual Property
Supply Chain
InMed (NASDAQ: INM) Positioned to Offer Rare Cannabinoid Manufacturing Technologies
February 15, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
February 14, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies
February 14, 2022
Via
CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals (NASDAQ: INM) to Release Q2 Financial Report, Update
February 11, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update
February 10, 2022
Via
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market
February 04, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition
February 03, 2022
Via
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Defining Value of Rare Cannabinoids in Pharma Space
February 03, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space
February 02, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed (NASDAQ: INM) Gains Potential to Synthetically Produce Rare Cannabinoids at Scale
February 02, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space
February 01, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals (NASDAQ: INM) Leveraging Growing Cannabinoid-Based Pharma Market
January 27, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
January 26, 2022
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market
January 26, 2022
Via
CannabisNewsWire
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 20, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 19, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT
January 19, 2022
Via
CannabisNewsWire
Topics
Supply Chain
Exposures
Supply Chain
InMed Pharmaceuticals’ (NASDAQ: INM) Issues Annual Shareholder Letter
January 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
January 05, 2022
Via
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
December 30, 2021
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
December 30, 2021
Via
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment
December 20, 2021
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.